Vitamin K supplements improve blood markers of vitamin K status but do not consistently slow down calcium buildup in blood vessels and heart valves, according to a 2026 review in Clinical Kidney Journal analyzing randomized trials. Vitamin K1 showed somewhat more promise than vitamin K2, particularly in dialysis patients receiving high doses, but neither form has been proven to prevent heart attacks, strokes, or death. The research shows vitamin K is biologically active but clinically unproven as a cardiovascular protection strategy in kidney disease.
Vitamin K has been studied as a potential way to prevent calcification, a condition where calcium builds up in blood vessels and heart valves, particularly in people with kidney disease. According to Gram Research analysis, while vitamin K supplements do improve blood markers showing better vitamin K status, the evidence that they actually slow down vessel hardening on imaging tests is mixed and inconsistent. Vitamin K1 shows somewhat more promise than vitamin K2, especially in dialysis patients receiving high doses, but neither form has been proven to reduce heart attacks, strokes, or death rates. The research suggests vitamin K is biologically active but not yet clinically proven as a heart protection strategy.
Key Statistics
A 2026 review of randomized trials in Clinical Kidney Journal found that while vitamin K1 and K2 supplements consistently improved blood markers of vitamin K status, this biochemical improvement did not uniformly translate into slowing calcification progression on imaging scans.
According to the 2026 Clinical Kidney Journal review, neither vitamin K1 nor vitamin K2 supplementation demonstrated reductions in major adverse cardiovascular events or mortality across available randomized trials, with studies that tracked these outcomes being too small to draw firm conclusions.
A 2026 review found that vitamin K1 produced more consistent evidence for slowing imaging-based calcification than vitamin K2, particularly in high-risk cohorts and hemodialysis populations receiving intensive dosing, though results remained heterogeneous across studies.
The 2026 Clinical Kidney Journal review concluded that vitamin K supplementation remains pharmacodynamically active but clinically unproven as a strategy to prevent cardiovascular endpoints in chronic kidney disease.
The Quick Take
- What they studied: Whether taking vitamin K supplements can prevent calcium buildup in blood vessels and heart valves, especially in people with chronic kidney disease
- Who participated: This was a review article that analyzed multiple randomized clinical trials testing vitamin K supplementation in various patient populations, with emphasis on kidney disease patients
- Key finding: Vitamin K supplements improve blood markers of vitamin K status, but this improvement does not consistently translate into actually slowing down calcium buildup seen on imaging scans. Vitamin K1 showed somewhat better results than vitamin K2, but neither prevented heart attacks or deaths
- What it means for you: If you have kidney disease or are at risk for vessel calcification, vitamin K supplements may not be the proven protective strategy doctors once hoped. Talk to your doctor before starting supplements, as the evidence remains uncertain and more research is needed
The Research Details
This is a comprehensive review article that examined all available randomized controlled trials testing vitamin K supplementation as a way to prevent vascular calcification. The researchers looked at studies using two main forms of vitamin K: vitamin K1 (phylloquinone) and vitamin K2 (menaquinone-7). They focused particularly on patients with chronic kidney disease, a group known to have both vitamin K deficiency and rapid calcium buildup in their blood vessels.
The review compared how well different vitamin K forms worked, what doses were used, how long studies lasted, and what outcomes were measured. Researchers examined both biochemical markers (blood tests showing vitamin K status) and imaging results (CT scans showing actual calcium deposits). They also looked for studies that tracked serious health events like heart attacks, strokes, and death.
This type of review is valuable because it synthesizes evidence from many individual studies to identify patterns and draw broader conclusions about whether a treatment actually works in real patients.
Understanding whether vitamin K supplementation truly prevents heart and vessel problems is crucial because many people with kidney disease face accelerated calcium buildup in their arteries and heart valves. If vitamin K worked as a preventive strategy, it would offer a safe, affordable intervention. However, the gap between improved blood markers and actual clinical benefit is important to understand, as it shows that just because a supplement changes measurable biological markers does not guarantee it prevents disease or saves lives.
This review was published in Clinical Kidney Journal, a peer-reviewed medical journal focused on kidney disease research. The authors systematically examined randomized controlled trials, which are considered the gold standard for testing whether treatments work. However, readers should note that the individual trials reviewed had varying quality, different patient populations, different vitamin K doses, and different ways of measuring outcomes. The fact that results were mixed and inconsistent across studies suggests the evidence base itself has limitations. The review’s strength lies in its honest assessment that biochemical improvement does not equal clinical benefit.
What the Results Show
Across all randomized trials reviewed, vitamin K supplementation consistently improved blood markers indicating better vitamin K status in the body. This shows the supplements are being absorbed and used. However, this biochemical improvement did not reliably translate into slowing down calcium deposits visible on imaging scans like CT scans.
Vitamin K1 (the form found in leafy greens) produced more consistent, though still mixed, evidence for slowing imaging-based calcification progression. This benefit appeared strongest in two specific groups: patients at very high risk for calcification and people undergoing hemodialysis (a kidney treatment) who received intensive high-dose vitamin K1 supplementation.
Vitamin K2 (menaquinone-7, found in fermented foods and supplements) did not produce reproducible benefits on imaging-based measures of vascular or heart valve calcification across the trials reviewed. Results were inconsistent and did not show clear benefit.
Most importantly, neither vitamin K1 nor vitamin K2 demonstrated reductions in major adverse cardiovascular events (heart attacks, strokes) or mortality (death rates). The few studies that tracked these serious health outcomes were too small to draw firm conclusions, and results were neutral, meaning vitamin K did not appear to prevent these events.
The review identified that patients with chronic kidney disease frequently have functional vitamin K deficiency, meaning their bodies cannot properly use the vitamin K available to them. This deficiency is linked to accelerated calcium buildup in vessels and valves. This biological connection makes vitamin K supplementation theoretically sound. However, correcting the deficiency at the biochemical level did not reliably prevent the clinical problem of calcification progression. The research also showed that vitamin K is required for activating a protein called matrix Gla protein, which naturally inhibits calcium deposits. Despite this clear biological mechanism, the clinical benefit remains unproven.
This review updates and clarifies the state of vitamin K research in kidney disease. Previous smaller studies and laboratory research suggested vitamin K might be protective, creating hope for a simple preventive strategy. However, as more rigorous randomized trials have been completed and analyzed together, the picture has become more complex. The review shows that initial biological plausibility and improved blood markers do not automatically translate into clinical benefit, a common pattern in medical research where promising mechanisms do not always produce real-world health improvements.
This review has several important limitations. First, individual trials reviewed varied significantly in study design, patient populations, vitamin K forms and doses used, treatment duration, and how outcomes were measured, making direct comparisons difficult. Second, most trials were relatively small and short-term, limiting ability to detect effects on serious health events. Third, the review itself did not conduct new research but synthesized existing studies, so conclusions are only as strong as the underlying evidence. Fourth, most trials focused on imaging-based outcomes rather than actual health events like heart attacks or death, which are more meaningful to patients. Finally, the review notes that studies were generally underpowered (too small) to detect differences in major cardiovascular events, so the neutral results for heart attacks and death do not definitively prove vitamin K does not help, only that current evidence does not support benefit.
The Bottom Line
At present, vitamin K supplementation cannot be recommended as a proven strategy to prevent cardiovascular complications in chronic kidney disease (confidence level: low to moderate). While vitamin K1 shows somewhat more promise than vitamin K2 based on imaging studies, the lack of demonstrated benefit on actual health events (heart attacks, strokes, death) means it should not be considered a primary prevention strategy. If you have kidney disease or risk factors for vascular calcification, focus on proven interventions like blood pressure control, managing phosphorus and calcium levels, and following your doctor’s treatment plan. If you are interested in vitamin K supplementation, discuss it with your nephrologist (kidney doctor) or cardiologist, as individual circumstances may vary.
This research is most relevant to people with chronic kidney disease, particularly those on dialysis, who face accelerated vascular calcification. It is also relevant to cardiologists and nephrologists considering whether to recommend vitamin K supplementation to high-risk patients. People without kidney disease should not assume these findings apply to them, as the research focused specifically on kidney disease populations. Healthy individuals eating a balanced diet typically get adequate vitamin K from food sources.
If vitamin K supplementation were to work, benefits would likely take months to years to appear, as vascular calcification is a slow process. Most trials reviewed lasted 6 months to 2 years. However, given that current evidence does not show clear clinical benefit even after this timeframe, waiting for vitamin K to prevent calcification is not a reliable strategy. Any changes in cardiovascular health from other interventions typically take weeks to months to become apparent.
Frequently Asked Questions
Does vitamin K prevent calcium buildup in arteries and heart valves?
Vitamin K supplements improve blood markers of vitamin K status, but evidence that they actually slow calcium buildup on imaging scans is mixed and inconsistent. Vitamin K1 shows somewhat better results than vitamin K2, but neither has been proven to prevent heart attacks or death.
Should people with kidney disease take vitamin K supplements?
Current evidence does not support vitamin K supplementation as a proven prevention strategy for kidney disease patients. Discuss with your nephrologist before starting supplements. Focus on proven interventions like blood pressure control and managing phosphorus and calcium levels.
What is the difference between vitamin K1 and vitamin K2?
Vitamin K1 (phylloquinone) is found in leafy greens and showed somewhat more promise in slowing calcification on imaging. Vitamin K2 (menaquinone-7) is found in fermented foods and supplements but did not produce reproducible benefits on vascular calcification in clinical trials.
Can vitamin K reduce the risk of heart attack or stroke?
No clinical trials have demonstrated that vitamin K supplementation reduces heart attacks, strokes, or death rates. While vitamin K improves blood markers, this has not translated into preventing major cardiovascular events in people with kidney disease.
How long does it take for vitamin K to prevent vascular calcification?
Most trials lasted 6 months to 2 years, but even with this timeframe, vitamin K did not consistently slow calcification progression on imaging. Given mixed results, vitamin K should not be relied upon as a primary prevention strategy.
Want to Apply This Research?
- If a user is taking vitamin K supplements under medical supervision, track weekly vitamin K intake (dose and form: K1 or K2) and any cardiovascular symptoms like chest discomfort, shortness of breath, or unusual fatigue. Also log kidney function markers if available from recent lab work.
- Users with kidney disease should use the app to track adherence to proven kidney protection strategies: blood pressure readings, phosphorus and calcium intake from food, medication compliance, and dialysis attendance. If considering vitamin K supplementation, log the decision and discuss it with their nephrologist through the app’s provider communication feature.
- Establish a quarterly check-in to review cardiovascular risk factors and kidney function trends. If vitamin K supplementation is being used, track any imaging results (CT scans showing calcification) and blood work showing vitamin K status. Monitor for any new cardiovascular symptoms. This long-term tracking helps identify whether supplementation is providing any measurable benefit in the individual user’s case.
This article summarizes research findings and should not be interpreted as medical advice. Vitamin K supplementation decisions should be made in consultation with your physician, nephrologist, or cardiologist, particularly if you have chronic kidney disease, take blood thinners like warfarin, or have other medical conditions. The evidence reviewed does not support vitamin K supplementation as a proven strategy to prevent cardiovascular complications, and individual circumstances may warrant different approaches. Always discuss supplement use with your healthcare provider before starting.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.